Please assess the completion status of the following clinical trial:

Trial Title: Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Give their signed written informed consent to participate.~* Are at least 40 years of age and no older than 80 at Visit 1.~* A female of non-child bearing potential or child bearing potential, has a negative serum pregnancy test, and agrees to approved contraceptive methods.~* COPD Diagnosis: Subjects with an established clinical history of COPD as defined by the American Thoracic Society(ATS)/European Respiratory Society (ERS).~* Current or former smokers with a history of at least 10 pack-years of cigarette smoking.~* FEV1/FVC ratio of \<0.70.~* Post-bronchodilator FEV1 must be ≥ 30% and \<80% predicted normal value calculated using the Third National Health and Nutrition Examination Survey (NHANES III) reference equations, and must also be greater than or equal to 750 mL.~* Subject is willing and, in the opinion of the Investigator, able to adjust current COPD therapy as required by the protocol.~Exclusion Criteria:~* Pregnancy, nursing females or subjects trying to conceive.~* Clinically significant neurologic, cardiovascular, hepatic, renal, endocrinologic, pulmonary, hematological, psychiatric, or other medical illness that would interfere with participation in this study.~* Current primary diagnosis of asthma.~* History of ECG abnormalities.~* Poorly controlled or worsening COPD prior to Screening or during the Screening Period.~* Clinically significant bladder neck obstruction or urinary retention.~* Male subjects with a trans-urethral resection of prostate (TURP) or full resection of the prostate within 6 months prior to Screening.~* Cancer that has not been in complete remission for at least five years.~* Inadequately treated glaucoma.~* History of allergic reaction or hypersensitivity to any component of the formulations used in this study.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (Type: EXPERIMENTAL): Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler (GFF MDI), PT003

Based on this trial design, predict the completion outcome and termination type (if applicable).